Table 1:
Clinical and Histological Characteristics at Diagnosis
| N (%) | |
|---|---|
| Age at diagnosis (years): median ± SD | 82.4 (±2.5) |
| 80–85 | 89 (83) |
| >85 | 18 (17) |
| Sex | |
| Male | 60 (56) |
| Female | 47 (44) |
| Karnofsky performance statusa | |
| ≤60 | 30 (33) |
| 70–80 | 37 (41) |
| ≥90 | 23 (26) |
| Comorbiditiesb | |
| Other malignancy | 22 (22) |
| Cerebrovascular | 9 (9) |
| Other neurological | 15 (15) |
| Cardiovascular | 38 (38) |
| Diabetes | 8 (8) |
| Hypertension | 51 (51) |
| Dyslipidemia | 14 (14) |
| Pulmonary | 8 (8) |
| Other | 56 (56) |
| None | 4 (4) |
| IDHc | |
| Wild type | 53 (96) |
| SEQ | 41 (75) |
| IHC | 12 (22) |
| Mutated | 2 (4) |
| MGMT promoterd | |
| Methylated | 20 (33) |
| Unmethylated | 41 (67) |
Abbreviations: IDH, isocitrate dehydrogenase 1/2; SEQ, IDH status determined by DNA sequencing; IHC, IDH status determined by immunohistochemistry; MGMT, O6-methylguanine DNA-methyltransferase.
aData available for 90 patients.
bData available for 100 patients.
cData available for 55 patients.
dData available for 61 patients.